scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1019449968 |
P356 | DOI | 10.1007/S00431-002-0981-1 |
P698 | PubMed publication ID | 12172829 |
P2093 | author name string | Andreas Sauerbrei | |
Stefan Burdach | |||
Gerd Horneff | |||
Barbara Uebe | |||
P433 | issue | 8 | |
P921 | main subject | herpes zoster | Q182155 |
P304 | page(s) | 442-444 | |
P577 | publication date | 2002-06-25 | |
P1433 | published in | European Journal of Pediatrics | Q15755736 |
P1476 | title | Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child | |
P478 | volume | 161 |
Q33774777 | A case of optic neuritis complicating herpes zoster ophthalmicus in a child |
Q38731791 | Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections |
Q34027426 | Emerging drugs for varicella-zoster virus infections |
Q37702470 | Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster |
Q40330700 | Genotype analysis of ORF 62 identifies varicella-zoster virus infections caused by a vaccine strain in children |
Q46084635 | Herpes zoster keratouveitis and inflammatory ocular hypertension 8 years after varicella vaccination |
Q35979111 | Herpes zoster ophthalmicus in an otherwise healthy 2-year-old child |
Q38547930 | Herpes zoster ophthalmicus: declining age at presentation |
Q53859755 | Molecular diagnosis of zoster post varicella vaccination. |
Q39632682 | Monitoring prevalence of varicella-zoster virus clades in Germany |
Q35047428 | Necrotizing fasciitis and streptococcal toxic shock syndrome secondary to varicella in a healthy child |
Q26863614 | Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data |
Q40150603 | Role of the JNK Pathway in Varicella-Zoster Virus Lytic Infection and Reactivation |
Q34590637 | Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. |
Q35666726 | Sero-Prevalence of Antibodies against Varicella Zoster Virus in Children under Seven-Years Old in 2012 in Tehran, Iran |
Q33900399 | The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA. |
Q38264045 | Varicella zoster virus vaccines: potential complications and possible improvements |
Search more.